ALE.P02

ALE.P02 · Alentis Therapeutics AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALE.P02, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors [Phase 1, Phase 2]

See pricing